Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Encinitas, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Encinitas, California--(Newsfile Corp. - March 10, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced three abstract acceptances for oral and poster presentation at the 2023 Association for Research in Vision and Ophthalmology (ARVO) meeting in New Orleans, La., April 23-27, 2023.

Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting

The stock price of Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) surged by 38.7% in the most recent trading session. This is why.

KPRX Stock: 38.7% Surge Explanation

Kiora Pharmaceuticals (NASDAQ: KPRX ) stock is heading higher on Tuesday thanks to an update on its KIO-101 eye drops. The big news here is the treatment getting investigational new drug application approval for a Phase 2 clinical trial.

Why Is Kiora Pharmaceuticals (KPRX) Stock Up 61% Today?

Intelligent Bio Solutions Inc

Lizhi

Innovative Eyewear Inc

Sidus Space

Seqll

Vaccinex Inc

Penny stocks to watch with news this month. The post 7 Penny Stocks To Watch With Big News In February; Time To Buy?

7 Penny Stocks To Watch With Big News In February; Time To Buy?

Shares of Kiora Pharmaceuticals Inc. KPRX, -7.34% soared about 57% in premarket trading on Tuesday after the company said it will begin a Phase 2 clinical trial for its experimental eye drops as a treatment for ocular rheumatoid arthritis. The study plans to enroll 120 patients in the first half of the year.

Kiora's stock rallies as eye drop treatment moves into mid-stage clinical trial

Encinitas, California--(Newsfile Corp. - February 7, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis and other autoimmune diseases (OPRA+).

Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases

Encinitas, California--(Newsfile Corp. - February 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has entered into a common stock purchase agreement for a committed equity financing (the "Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC"), a long-standing investor in the Company.

Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital

- Kiora is advancing a pipeline of therapeutics for rare and underserved ophthalmic diseases - - Anticipates reporting results in 1H 2023 from two clinical studies, one in patients with Retinitis Pigmentosa and another in patients with persistent corneal epithelial defects - - Expects to initiate Phase 2 trial in autoimmune disease patients experiencing ocular surface disease - Encinitas, California--(Newsfile Corp. - January 9, 2023) - Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website

Encinitas, California--(Newsfile Corp. - January 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced enrollment has been completed in its clinical study evaluating KIO-201 in patients with Persistent Corneal Epithelial Defects ("PCED"), a rare ocular condition characterized by non-healing wounds on the surface of the eye. Results from the study are expected to be reported at an upcoming medical conference in the first half of 2023.

Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023

Salt Lake City, Utah--(Newsfile Corp. - November 18, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced today it has entered into warrant inducement offer letters to raise $3.12 million in gross proceeds from the exercise of 654,609 Class A warrants issued in the Company's public offering from July 2022. On November 17, 2022, the Company reduced the exercise price of all Class A warrants from $8.00 per share to $4.

Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants

Salt Lake City, Utah--(Newsfile Corp. - November 17, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced today the dosing of the first patient in a first-in-human open-label clinical trial for KIO-301, intended to restore vision loss in patients with Retinitis Pigmentosa (RP). RP is a rare, inherited genetic eye disease resulting in degeneration of the retinal photoreceptors (rods and cones) and often significant loss of functional vision.

Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa

Salt Lake City, Utah--(Newsfile Corp. - November 9, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is providing a business update and reporting financial results for the three and nine months ended September 30, 2022.Management Discussion: "We're advancing a diverse development pipeline of three differentiated assets across rare and narrowly-defined patient populations requiring new treatment options for ophthalmic disease," said Brian M. Strem, Ph.D.

Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year's End

Salt Lake City, Utah--(Newsfile Corp. - October 17, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results from a Phase 1 study of KIO-100 (formerly PP-001) demonstrate its potential as a treatment for non-infectious uveitis, an ophthalmic inflammatory disease.

Kiora Pharmaceuticals Announces Publication of Phase 1 Trial Results for KIO-100 as a Treatment for Ocular Inflammatory Disease

Salt Lake City, Utah--(Newsfile Corp. - October 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today that it has received a Bid Price Compliance Letter from The Nasdaq Stock Market LLC ("Nasdaq") on October 12, 2022 informing Kiora that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Dallas, Texas--(Newsfile Corp. - September 28, 2022) - Stonegate Capital Partners will host a virtual investor event with ophthalmology experts to discuss Retinitis Pigmentosa (RP) and the pipeline of products in development. Participants will include Christine Kay, M.D., Vitreoretinal surgeon and IRD specialist at Vitreoretinal Associates, Eric Daniels, M.D., CDO of Kiora Pharmaceuticals (NASDAQ: KPRX) and Ben Shaberman, Ph.D.

Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held October 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D.

Source: iQoncept / Shutterstock Kiora Pharmaceuticals (NASDAQ: KPRX ) stock is in the news Tuesday as traders wonder what has the company's shares seeing wild movement. The big news affecting KPRX stock today is a reverse stock split.

What Is Going on With Kiora Pharmaceuticals (KPRX) Stock Today?

Salt Lake City, Utah--(Newsfile Corp. - September 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that its stockholders authorized a reverse stock split of the Company's common stock. Following the annual stockholder meeting, the board of directors approved a reverse stock split of one share of common stock for every 40 shares of common stock.

Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split

Aditxt Inc

Comera Life Sciences Holdings Inc

Here's what you need to know about buying penny stocks today The post Top Penny Stocks to Watch After the Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch After the Market Crash

Salt Lake City, Utah--(Newsfile Corp. - September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of Finance. Mrs. Tosca will join the executive management team and oversee finance, SEC reporting and accounting functions as well as play a role in the company's capital markets strategy and planning.

Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance

Kaival Brands Innovations Group

Nokia

Which penny stocks are you watching today? The post Best Penny Stocks to Buy Right Now?

Best Penny Stocks to Buy Right Now? Check These 3 Out

Salt Lake City, Utah--(Newsfile Corp. - August 12, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is reporting financial results for the three and six months ended June 30, 2022."In the first half, we continued to advance three core programs toward their next phase of clinical development," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora.

Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results

Salt Lake City, Utah--(Newsfile Corp. - July 28, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has been granted a U.S. patent covering hydrogel-based sustained release platforms, inclusive of KIO-201, which enable controlled release of antibiotics for the treatment of ocular diseases. The intellectual property, US Patent No.

Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics

Salt Lake City, Utah--(Newsfile Corp. - July 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the closing of an underwritten public offering for gross proceeds of approximately $6.0 million, which includes full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses.

Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

Salt Lake City, Utah--(Newsfile Corp. - July 22, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the pricing of an underwritten public offering for gross proceeds of approximately $5.2 million prior to deducting underwriting discounts and commissions and offering expenses.The offering is comprised of (i) 19,770,172 shares of common stock, (ii) 1,280 shares of Series E convertible preferred stock, (iii) 26,170,172 Class A Warrants with an exercise price of $0.20...

Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering

Salt Lake City, Utah--(Newsfile Corp. - July 5, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced enrolling the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with Persistent Corneal Epithelial Defect (PCED), a rare ocular surface condition characterized by non-healing wounds on the eye surface. "We believe KIO-201 has the potential to address a rare ophthalmic condition in patients who have...

News for Kiora Pharmaceuticals Stock (KPRX)